Reference
Lymphoma research foundation. [Internet; cited November 2018]. Available at:
Swerdlow SH, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. In: World Health Organization Classification of Tumours. Lyon, France: IARC; 2017.
American Cancer Society. What is Non-Hodgkin Lymphoma. [Internet; cited November 2018]. Available at:
A clinical evaluation of the International Lymphoma Study Group classification of non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Classification Project. Blood 1997; 89:3909-18.
Globocan 2018. World fact sheet. [Internet; cited November 2018]. Available at:
Very Well Health. [Internet; cited November 2018] Available at:
Lymphoma Action. [Internet; cited November 2018]. Available at:
Lymphoma Research Foundation. [Internet; cited November 2018]. Available at:
Medscape. Diffuse large cell lymphoma. [Internet; cited November 2018]. Available at:
Rovira J et al. Prognosis of patients with diffuse large B cell lymphoma not reaching complete response or relapsing after frontline chemotherapy or immunochemotherapy. Ann Hematol. 2015; 94: 803–812.
Salles GA. Clinical features, prognosis and treatment of follicular lymphoma. Hematology Am Soc Hematol Educ Program 2007; 1:216-225.
Lymphoma Research Foundation. [Internet; cited November 2018]. Available at:
Maurer, MJ et al. Event-free survival at 24 months is a robust end point for disease-related outcome in diffuse large B-cell lymphoma treated with immunochemotherapy. J Clin Oncol. 2014; 32: 1066-73.
Vaidya R & Witzig TE. Prognostic factors for diffuse large B-cell lymphoma in the R(X)CHOP era. Annals of Oncology 2014; 25:2124–2133.
Fowler N. Role of Maintenance Rituximab (Rituxan) Therapy In the Treatment of Follicular Lymphoma. Pharmacy and Therapeutics; 2011; 36:590-598
Dotan E, et al. Impact of rituximab (Rituxan) on the treatment of B-cell non-hodgkin’s lymphoma. Pharmacy and Therapeutics.2010;35:148-57.
M-BA-00000009
Roche d.o.o. - Roche Ltd, Zmaja od Bosne 7, 71000 Sarajevo, Bosna i Hercegovina